Skip to main content
SpringerLink
Log in

Heart Failure Treatment in 2023: Is There a Place for Lipid Lowering Therapy?

  • Review
  • Published:
Current Atherosclerosis Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

An evidence for lipid lowering therapy in heart failure is briefly summarized in this review.

Recent Findings

Heart failure therapy is based on recent guidelines for diagnosis and treatment of acute and chronic heart failure. The question of the importance of hypolipidemic treatment in heart failure remains insufficiently answered. We still rely only on results of two randomized controlled trials that did not show significant benefit of statins on mortality in these patients. In contrast, some meta-analysis, prospective or retrospective cohorts, found some positive effects of this therapy. Recently, the role of inflammation and the possibility of its influence by hypolipidemics have been discussed. PCSK9 inhibitors, new lipid lowering drugs, are very effective in LDL-cholesterol lowering and atherosclerotic cardiovascular diseases prevention. The role of PCSK9 inhibitors in heart failure treatment is investigated.

Summary

Based on current knowledge, hypolipidemics are not generally recommended in heart failure therapy, unless there is another indication for their use.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Bozkurt B, Coats AJS, Tsutsui H, Abdelhamid CM, Adamopoulos S, Albert N, et al. Universal definition and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure: Endorsed by the Canadian Heart Failure Society, Heart Failure Association of India, Cardiac Society of Australia and New Zealand, and Chinese Heart Failure Association. Eur J Heart Fail. 2021;23(3):352–80.

    Article  PubMed  Google Scholar 

  2. McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599–726.

    Article  CAS  PubMed  Google Scholar 

  3. Yan T, Zhu S, Yin X, Xie C, Xue J, Zhu M, et al. Burden, trends, and inequalities of heart failure globally, 1990 to 2019: a secondary analysis based on the global burden of disease 2019 study. J Am Heart Assoc Cardiovasc Cerebrovasc Dis. 2023;12(6):e027852.

    Article  Google Scholar 

  4. Riccardi M, Sammartino AM, Piepoli M, Adamo M, Pagnesi M, Rosano G, et al. Heart failure: an update from the last years and a look at the near future. ESC Heart Fail. 2022;9(6):3667–93.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Sharma A, Verma S, Bhatt DL, Connelly KA, Swiggum E, Vaduganathan M, et al. Optimizing foundational therapies in patients with HFrEF: how do we translate these findings into clinical care? JACC Basic Transl Sci. 2022;7(5):504–17.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Kittleson MM, Panjrath GS, Amancherla K, Davis LL, Deswal A, Dixon DL, et al. 2023 ACC Expert Consensus Decision Pathway on management of heart failure with preserved ejection fraction: a report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2023;81(18):1835–78.

    Article  PubMed  Google Scholar 

  7. Solomon SD, McMurray JJV, Claggett B, de Boer RA, DeMets D, Hernandez AF, et al. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med. 2022;387(12):1089–98.

    Article  PubMed  Google Scholar 

  8. Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, Böhm M, et al. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021;385(16):1451–61.

    Article  CAS  PubMed  Google Scholar 

  9. Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, et al. 2022 AHA/ACC/HFSA Guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on clinical practice guidelines. Circulation. 2022;145(18):e895–1032.

    PubMed  Google Scholar 

  10. McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al. Focused update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2023;2023:ehad195.

    Google Scholar 

  11. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice | European Heart Journal | Oxford Academic [Internet]. [cited 2023 Jun 26]. https://academic.oup.com/eurheartj/article/42/34/3227/6358713?login=false

  12. Ference BA, Ginsberg HN, Graham I, Ray KK, Packard CJ, Bruckert E, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2017;38(32):2459–72.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Ray KK, Raal FJ, Kallend DG, Jaros MJ, Koenig W, Leiter LA, et al. Inclisiran and cardiovascular events: a patient-level analysis of phase III trials. Eur Heart J. 2023;44(2):129–38.

    Article  CAS  PubMed  Google Scholar 

  14. Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111–88.

    Article  PubMed  Google Scholar 

  15. Pedersen TR. Pleiotropic effects of statins: evidence against benefits beyond LDL-cholesterol lowering. Am J Cardiovasc Drugs Drugs Devices Interv. 2010;10(Suppl 1):10–7.

    Article  CAS  Google Scholar 

  16. Marzilli M. Pleiotropic effects of statins: evidence for benefits beyond LDL-cholesterol lowering. Am J Cardiovasc Drugs Drugs Devices Interv. 2010;10(Suppl 1):3–9.

    Article  CAS  Google Scholar 

  17. Bugiardini R, Yoon J, Mendieta G, Kedev S, Zdravkovic M, Vasiljevic Z, et al. Reduced heart failure and mortality in patients receiving statin therapy before initial acute coronary syndrome. J Am Coll Cardiol. 2022;79(20):2021–33.

    Article  PubMed  Google Scholar 

  18. Cholesterol Treatment Trialists’ (CTT) Collaboration, Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet Lond Engl. 2010;376(9753):1670–81.

    Article  Google Scholar 

  19. Velavan P, Huan Loh P, Clark A, Cleland JGF. The cholesterol paradox in heart failure. Congest Heart Fail Greenwich Conn. 2007;13(6):336–41.

    Article  Google Scholar 

  20. Horwich TB, Hamilton MA, Maclellan WR, Fonarow GC. Low serum total cholesterol is associated with marked increase in mortality in advanced heart failure. J Card Fail. 2002;8(4):216–24.

    Article  CAS  PubMed  Google Scholar 

  21. Greene SJ, Vaduganathan M, Lupi L, Ambrosy AP, Mentz RJ, Konstam MA, et al. Prognostic significance of serum total cholesterol and triglyceride levels in patients hospitalized for heart failure with reduced ejection fraction (from the EVEREST Trial). Am J Cardiol. 2013;111(4):574–81.

    Article  CAS  PubMed  Google Scholar 

  22. Gupta PP, Fonarow GC, Horwich TB. Obesity and the obesity paradox in heart failure. Can J Cardiol. 2015;31(2):195–202.

    Article  PubMed  Google Scholar 

  23. Horwich TB, Fonarow GC, Clark AL. Obesity and the obesity paradox in heart failure. Prog Cardiovasc Dis. 2018;61(2):151–6.

    Article  PubMed  Google Scholar 

  24. Rossignol P, Masson S, Barlera S, Girerd N, Castelnovo A, Zannad F, et al. Loss in body weight is an independent prognostic factor for mortality in chronic heart failure: insights from the GISSI-HF and Val-HeFT trials. Eur J Heart Fail. 2015;17(4):424–33.

    Article  PubMed  Google Scholar 

  25. Kjekshus J, Dunselman P, Blideskog M, Eskilson C, Hjalmarson A, McMurray JV, et al. A statin in the treatment of heart failure? Controlled rosuvastatin multinational study in heart failure (CORONA): study design and baseline characteristics. Eur J Heart Fail. 2005;7(6):1059–69.

    Article  CAS  PubMed  Google Scholar 

  26. Tavazzi L, Maggioni AP, Marchioli R, Barlera S, Franzosi MG, Latini R, et al. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet Lond Engl. 2008;372(9645):1231–9.

    Article  Google Scholar 

  27. Cleland JGF, McMurray JJV, Kjekshus J, Cornel JH, Dunselman P, Fonseca C, et al. Plasma concentration of amino-terminal pro-brain natriuretic peptide in chronic heart failure: prediction of cardiovascular events and interaction with the effects of rosuvastatin: a report from CORONA (Controlled Rosuvastatin Multinational Trial in Heart Failure). J Am Coll Cardiol. 2009;54(20):1850–9.

    Article  CAS  PubMed  Google Scholar 

  28. Wang JQ, Wu GR, Wang Z, Dai XP, Li XR. Long-term clinical outcomes of statin use for chronic heart failure: a meta-analysis of 15 prospective studies. Heart Lung Circ. 2014;23(2):105–13.

    Article  CAS  PubMed  Google Scholar 

  29. Al-Gobari M, Le HH, Fall M, Gueyffier F, Burnand B. No benefits of statins for sudden cardiac death prevention in patients with heart failure and reduced ejection fraction: a meta-analysis of randomized controlled trials. PLoS One. 2017;12(2):e0171168.

    Article  PubMed  PubMed Central  Google Scholar 

  30. Bielecka-Dabrowa A, Bytyçi I, Von Haehling S, Anker S, Jozwiak J, Rysz J, et al. Association of statin use and clinical outcomes in heart failure patients: a systematic review and meta-analysis. Lipids Health Dis. 2019;18(1):188.

    Article  PubMed  PubMed Central  Google Scholar 

  31. • Lee MS, Duan L, Clare R, Hekimian A, Spencer H, Chen W. Comparison of effects of statin use on mortality in patients with heart failure and preserved versus reduced left ventricular ejection fraction. Am J Cardiol. 2018;122(3):405–12. Authors compare the effect of statin therapy in patients with heart failure with reduced and preserved ejection fraction. It is one of the few studies in patients with HFpEF.

    Article  CAS  PubMed  Google Scholar 

  32. Liu G, Zheng XX, Xu YL, Ru J, Hui RT, Huang XH. Meta-analysis of the effect of statins on mortality in patients with preserved ejection fraction. Am J Cardiol. 2014;113(7):1198–204.

    Article  CAS  PubMed  Google Scholar 

  33. Alehagen U, Benson L, Edner M, Dahlström U, Lund LH. Association between use of statins and outcomes in heart failure with reduced ejection fraction: prospective propensity score matched cohort study of 21 864 patients in the Swedish Heart Failure Registry. Circ Heart Fail. 2015;8(2):252–60.

    Article  CAS  PubMed  Google Scholar 

  34. Kim MN, Park SM. Current status of pharmacologic and nonpharmacologic therapy in heart failure with preserved ejection fraction. Heart Fail Clin. 2021;17(3):463–82.

    Article  PubMed  Google Scholar 

  35. Paulus WJ, Tschöpe C. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J Am Coll Cardiol. 2013;62(4):263–71.

    Article  PubMed  Google Scholar 

  36. Borlaug BA, Sharma K, Shah SJ, Ho JE. Heart failure with preserved ejection fraction: JACC scientific statement. J Am Coll Cardiol. 2023;81(18):1810–34.

    Article  PubMed  Google Scholar 

  37. Sanders-van Wijk S, Tromp J, Beussink-Nelson L, Hage C, Svedlund S, Saraste A, et al. Proteomic evaluation of the comorbidity-inflammation paradigm in heart failure with preserved ejection fraction: results from the PROMIS-HFpEF study. Circulation. 2020;142(21):2029–44.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Rao VN, Zhao D, Allison MA, Guallar E, Sharma K, Criqui MH, et al. Adiposity and incident heart failure and its subtypes: MESA (multi-ethnic study of atherosclerosis). JACC Heart Fail. 2018;6(12):999–1007.

    Article  PubMed  PubMed Central  Google Scholar 

  39. Samson R, Le Jemtel TH. Therapeutic stalemate in heart failure with preserved ejection fraction. J Am Heart Assoc. 2021;10(12):e021120.

    Article  PubMed  PubMed Central  Google Scholar 

  40. Venkateshvaran A, Faxen UL, Hage C, Michaëlsson E, Svedlund S, Saraste A, et al. Association of epicardial adipose tissue with proteomics, coronary flow reserve, cardiac structure and function, and quality of life in heart failure with preserved ejection fraction: insights from the PROMIS-HFpEF study. Eur J Heart Fail. 2022;24(12):2251–60.

    Article  CAS  PubMed  Google Scholar 

  41. Martín-Ventura JL, Blanco-Colio LM, Gómez-Hernández A, Muñoz-García B, Vega M, Serrano J, et al. Intensive treatment with atorvastatin reduces inflammation in mononuclear cells and human atherosclerotic lesions in one month. Stroke. 2005;36(8):1796–800.

    Article  PubMed  Google Scholar 

  42. Ridker PM, Danielson E, Fonseca FAH, Genest J, Gotto AM, Kastelein JJP, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359(21):2195–207.

    Article  CAS  PubMed  Google Scholar 

  43. Wojnicz R, Wilczek K, Nowalany-Kozielska E, Szyguła-Jurkiewicz B, Nowak J, Poloński L, et al. Usefulness of atorvastatin in patients with heart failure due to inflammatory dilated cardiomyopathy and elevated cholesterol levels. Am J Cardiol. 2006;97(6):899–904.

    Article  CAS  PubMed  Google Scholar 

  44. Winter MP, Sulzgruber P, Koller L, Bartko P, Goliasch G, Niessner A. Immunomodulatory treatment for lymphocytic myocarditis-a systematic review and meta-analysis. Heart Fail Rev. 2018;23(4):573–81.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. • Tuñón J, Badimón L, Bochaton-Piallat ML, Cariou B, Daemen MJ, Egido J, et al. Identifying the anti-inflammatory response to lipid lowering therapy: a position paper from the working group on atherosclerosis and vascular biology of the European Society of Cardiology. Cardiovasc Res. 2019;115(1):10–9. This is an interesting paper focused on the anti-inflammatory effect of lipid lowering therapy, which could play an important role in patients with heart failure.

    Article  PubMed  Google Scholar 

  46. Shah SJ, Lam CSP, Svedlund S, Saraste A, Hage C, Tan RS, et al. Prevalence and correlates of coronary microvascular dysfunction in heart failure with preserved ejection fraction: PROMIS-HFpEF. Eur Heart J. 2018;39(37):3439–50.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  47. Hwang SJ, Melenovsky V, Borlaug BA. Implications of coronary artery disease in heart failure with preserved ejection fraction. J Am Coll Cardiol. 2014;63(25 Pt A):2817–27.

    Article  PubMed  Google Scholar 

  48. Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376(18):1713–22.

    Article  CAS  PubMed  Google Scholar 

  49. Schwartz GG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med. 2018;379(22):2097–107.

    Article  CAS  PubMed  Google Scholar 

  50. Xu Q, Zhao YM, He NQ, Gao R, Xu WX, Zhuo XJ, et al. PCSK9: a emerging participant in heart failure. Biomed Pharmacother Biomed Pharmacother. 2023;158:114106.

    Article  CAS  PubMed  Google Scholar 

  51. Da Dalt L, Castiglioni L, Baragetti A, Audano M, Svecla M, Bonacina F, et al. PCSK9 deficiency rewires heart metabolism and drives heart failure with preserved ejection fraction. Eur Heart J. 2021;42(32):3078–90.

    Article  PubMed  PubMed Central  Google Scholar 

  52. Francis GS. Cholesterol and heart failure: is there an important connection? J Am Coll Cardiol. 2017;70(17):2137–8.

    Article  PubMed  Google Scholar 

  53. • Bayes-Genis A, Núñez J, Zannad F, Ferreira JP, Anker SD, Cleland JG, et al. The PCSK9-LDL receptor axis and outcomes in heart failure: BIOSTAT-CHF subanalysis. J Am Coll Cardiol. 2017;70(17):2128–36. This an important work focused on interesting findings in the area of PCSK9-LDL receptor axis, PCSK9 inhibitors, and their possible influence in heart failure.

    Article  CAS  PubMed  Google Scholar 

  54. Bayes-Genis A, Lupón J, Revuelta-Lopez E, Llibre C, Gastelurrutia P, Domingo M, Cediel G, Codina P, Santiago-Vacas E, Rangel-Sousa D, Fernández-Cisnal A, Miñana G, Mollar A, Núñez J. Evolocumab has no effects on heart failure with reduced ejection fraction injury biomarkers: The EVO-HF trial. Eur J Heart Fail. 2023;25(8):1439–43. https://doi.org/10.1002/ejhf.2932.

    Article  CAS  PubMed  Google Scholar 

  55. Karatasakis A, Danek BA, Karacsonyi J, Rangan BV, Roesle MK, Knickelbine T, et al. Effect of PCSK9 inhibitors on clinical outcomes in patients with hypercholesterolemia: a meta-analysis of 35 randomized controlled trials. J Am Heart Assoc. 2017;6(12):e006910.

    Article  PubMed  PubMed Central  Google Scholar 

  56. White HD, Schwartz GG, Szarek M, Bhatt DL, Bittner VA, Chiang CE, et al. Alirocumab after acute coronary syndrome in patients with a history of heart failure. Eur Heart J. 2022;43(16):1554–65.

    Article  CAS  PubMed  Google Scholar 

  57. Niessner A, Drexel H. PCSK9 inhibition in patients with heart failure: neutral or harmful intervention? Eur Heart J. 2022;43(16):1566–8.

    Article  PubMed  Google Scholar 

  58. Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, et al. AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines. Circulation [Internet]. 2018, 2019;139(25). https://doi.org/10.1161/CIR.0000000000000625.

Download references

Funding

This work was supported by the project National Institute for Research of Metabolic and Cardiovascular Diseases (Programme EXCELES, ID Project No. LX22NPO5104) – Funded by the European Union – Next Generation EU.

Author information

Authors and Affiliations

  1. Department of Cardiovascular Diseases, St Anne’s University Hospital and Masaryk, University Brno, Brno, Czech Republic

    Hana Poloczková & Jan Krejčí

Authors
  1. Hana Poloczková
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jan Krejčí
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

H.P. wrote the main manuscript text and both authors reviewed the manuscript.

Corresponding author

Correspondence to Jan Krejčí.

Ethics declarations

Competing Interests

The authors declare no competing interests.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Poloczková, H., Krejčí, J. Heart Failure Treatment in 2023: Is There a Place for Lipid Lowering Therapy?. Curr Atheroscler Rep 25, 957–964 (2023). https://doi.org/10.1007/s11883-023-01166-3

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11883-023-01166-3

Keywords

Search

Navigation